---
document_datetime: 2025-01-06 16:14:37
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/inbrija-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: inbrija-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 3.7332022
conversion_datetime: 2025-12-24 02:03:56.761164
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Inbrija

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                            | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                           |
|----------------------|--------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------|
| N/0024               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 18/12/2024                          |                                             | PL                               |                                   |
| PSUSA/10780 0/202312 | Periodic Safety Update EU Single assessment - levodopa                                           | 11/07/2024                          | n/a                                         |                                  | PRAC Recommendation - maintenance |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| R/0022               | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                            | 25/04/2024   | 13/06/2024   |                        |                                   |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------|-----------------------------------|
| PSUSA/10780 0/202306 | Periodic Safety Update EU Single assessment - levodopa                                                                                                                                                                                                                                                                                                                                             | 11/01/2024   | n/a          |                        | PRAC Recommendation - maintenance |
| IAIN/0021            | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                 | 08/12/2023   | n/a          |                        |                                   |
| PSUSA/10780 0/202212 | Periodic Safety Update EU Single assessment - levodopa                                                                                                                                                                                                                                                                                                                                             | 06/07/2023   | n/a          |                        | PRAC Recommendation - maintenance |
| IB/0018/G            | This was an application for a group of variations. B.III.2.z - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Other variation B.III.2.z - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Other variation B.III.2.z - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Other variation | 04/05/2023   | n/a          |                        |                                   |
| IB/0017/G            | This was an application for a group of variations. B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g.                                            | 28/04/2023   | 14/03/2024   | SmPC, Labelling and PL |                                   |

<div style=\"page-break-after: always\"></div>

|                      | tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes                                                                                                                                                                                                    |            |            |    |                                   |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|-----------------------------------|
| PSUSA/10780 0/202206 | Periodic Safety Update EU Single assessment - levodopa                                                                                                                                                                                                                                                | 12/01/2023 | n/a        |    | PRAC Recommendation - maintenance |
| IAIN/0015            | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                    | 25/11/2022 | n/a        |    |                                   |
| PSUSA/10780 0/202112 | Periodic Safety Update EU Single assessment - levodopa                                                                                                                                                                                                                                                | 07/07/2022 | n/a        |    | PRAC Recommendation - maintenance |
| IA/0013/G            | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.f.1.e - Stability of FP - Change to an approved stability protocol | 19/04/2022 | n/a        |    |                                   |
| PSUSA/10780 0/202106 | Periodic Safety Update EU Single assessment - levodopa                                                                                                                                                                                                                                                | 13/01/2022 | n/a        |    | PRAC Recommendation - maintenance |
| N/0011               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                      | 20/12/2021 | 14/03/2024 | PL |                                   |
| N/0009               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                      | 05/11/2021 | 14/03/2024 | PL |                                   |

<div style=\"page-break-after: always\"></div>

| PSUSA/10780 0/202012   | Periodic Safety Update EU Single assessment - levodopa                                                                                                                                                                                                                                                                                                                                                                   | 08/07/2021   | n/a        |             | PRAC Recommendation - maintenance                                                                                                           |
|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0007/G            | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites | 05/07/2021   | n/a        |             |                                                                                                                                             |
| PSUSA/10780 0/202006   | Periodic Safety Update EU Single assessment - levodopa                                                                                                                                                                                                                                                                                                                                                                   | 28/01/2021   | 26/03/2021 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/107800/202006. |
| IB/0005                | B.IV.1.a.1 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging - Device with CE marking                                                                                                                                                                                                                                      | 18/11/2020   | n/a        |             |                                                                                                                                             |
| IB/0003                | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                                                                                                                                     | 15/10/2020   | n/a        |             |                                                                                                                                             |
| IA/0004/G              | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release                                                                                                                                                                                                                                                                                                                        | 28/09/2020   | n/a        |             |                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

|                      | arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test   |            |            |             |                                                                                                                                             |
|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10780 0/201912 | Periodic Safety Update EU Single assessment - levodopa                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 23/07/2020 | 24/09/2020 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/107800/201912. |